Association between Plasma Ceramides and Vascular Events: A Meta-analysis

doi:10.3969/j.issn.1673-5765.2022.04.008

Abstract

Abstract: Objective To explore the relationship between plasma ceramides (Cer) and risk of cardiocerebrovascular events in patients with cardiovascular risk factors. Methods The databases including PubMed, Embase, Web of Science, CNKI, Wanfang Data and VIP were retrieved to search for the clinical studies involving the association of Cer and the risk of major adverse cardiovascular events (MACE) or stroke or myocardial infarction. A tool for assessing risk of bias in non-randomised studies of interventions (ROBINS-Ⅰ) was used to assess the literature quality in this study. Cer indices included ceramide test 2 (CERT2) score and Cer components of CERT2. According to heterogeneity analysis, a fixed or random effect metaanalysis was performed to determine the relationship between the above Cer indices and cardiocerebrovascular events. Results A total of 7 cohort studies including 30 886 patients were included in this meta-analysis. The results showed that particular components of Cer (d18:1/16:0) (HR 1.13, 95%CI 1.02-1.24, P =0.013) was independent risk factors of MACE. However, no obvious association between Cer (d18:1/24:0) or Cer (d18:1/24:1) and MACE were observed. There were no obvious association between CERT2 and stroke or myocardial infarction.Conclusions Cer (d18:1/16:0) was the risk factor of MACE. CERT2 might not be a robust predictor of stroke or myocardial infarction.

Key words: Ceramide; Risk factor; Major adverse cardiovascular event; Stroke; Myocardial infarction

摘要：

目的用meta分析方法评价血浆神经酰胺（ceramide，Cer）水平与存在心血管疾病风险因素人群的不良心脑血管事件发生风险之间的相关性。

方法计算机检索PubMed、Embase、Web of Science、中国知网、万方和维普数据库，查找评价血浆Cer与不良心血管事件（major adverse cardiovascular events，MACE）或心肌梗死或卒中发生风险相关性的临床研究。利用非随机干预研究偏移风险评估工具（risk of bias in non-randomised studies of interventions，ROBINS-I）进行文献质量评价。Cer指标包括新神经酰胺测试2（ceramide test 2，CERT2）评分及其中包括的不同Cer组分。根据异质性分析结果，分别采用固定或随机效应模型进行不同Cer指标与不良心脑血管事件之间的相关性分析。

结果纳入7项针对存在心血管疾病风险因素人群的队列研究，共30 886例受试者。meta分析结果显示，CERT2评分内的特定Cer组分Cer（d18∶1/16∶0）（HR 1.13，95%CI 1.02～1.24，P =0.013）是MACE风险升高的独立危险因素，而Cer（d18∶1/24∶0）和Cer（d18∶1/24∶1）与MACE风险无相关性。CERT2评分与单独卒中或心肌梗死发生之间无相关性。

结论 Cer（d18∶1/16∶0）是MACE的危险因素。CERT2评分可能不能作为预测卒中或心肌梗死的工具。未来仍需高质量临床研究对本结论进一步论证。

关键词: 神经酰胺; 危险因素; 不良心血管事件; 卒中; 心肌梗死

YANG Chengyuan, JIN Aoming, XU Jie, MENG Xia. Association between Plasma Ceramides and Vascular Events: A Meta-analysis[J]. Chinese Journal of Stroke, 2022, 17(04): 365-372.

杨程缘, 金奥铭, 许杰, 孟霞. 血浆神经酰胺与血管性事件相关性的meta分析[J]. 中国卒中杂志, 2022, 17(04): 365-372.

References

[1] GBD 2016 Causes of Death Collaborators. Global，regional，and national age-sex specific mortality for 264 causes of death，1980-2016：a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet，2017，390（10100）：1151-1210.
[2] WANG W Z，JIANG B，SUN H X，et al. Prevalence，incidence，and mortality of stroke in China：results from a nationwide population-based survey of 480 687 adults[J]. Circulation，2017，135（8）：759-771.
[3] CHAURASIA B，SUMMERS S A. Ceramides in metabolism：key lipotoxic players[J/OL]. Annu Rev Physiol，2021，83：303-330[2021-11-01]. https://doi.org/10.1146/annurev-physiol-031620-093815.
[4] KURZ J，PARNHAM M J，GEISSLINGER G，et al. Ceramides as novel disease biomarkers[J]. Trends Mol Med，2019，25（1）：20-32.
[5] HILVO M，MEIKLE P J，PEDERSEN E R，et al.Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients[J]. Eur Heart J，2020，41（3）：371-380.

[6] LAAKSONEN R，EKROOS K，SYSI-AHO M，et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J，2016，37（25）：1967-1976.
[7] PAPAZOGLOU A S，STALIKAS N，MOYSIDIS D V，et al. CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events：a systematic review and meta-analysis[J/OL]. J Clin Lipidol，2022，S1933-2874（22）00028-9[2021-11-11]. https://doi.org/10.1016/j.jacl.2022.02.001.
[8] STERNE J A，HERNAN M A，REEVES B C，et al. ROBINS-I：a tool for assessing risk of bias in non-randomised studies of interventions[J/OL]. BMJ，2016，355：i4919[2021-11-11]. https://doi.org/10.1136/bmj.i4919.
[9] DE CARVALHO L P，TAN S H，OW G S，et al. Plasma ceramides as prognostic biomarkers and their arterial and myocardial tissue correlates in acute myocardial infarction[J]. JACC Basic Transl Sci，2018，3（2）：163-175.
[10] YIN W，LI F，TAN X，et al. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk[J/OL]. Am J Hypertens，2021：hpab105[2021-11-11]. https://doi.org/10.1093/ajh/hpab105.
[11] MUNDRA P A，BARLOW C K，NESTEL P J，et al. Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention[J/OL]. JCI Insight，2018，3（17）：e121326[2021-11-11]. https://doi.org/10.1172/jci.insight.121326.[12] GENCER B，MORROW D A，BRAUNWALD E，et al. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome[J/OL]. Eur J Prev Cardiol，2020：zwaa143[2021-11-11].https://doi.org/10.1093/eurjpc/zwaa143.
[13] HILVO M，WALLENTIN L，GHUKASYAN LAKIC T，et al. Prediction of residual risk by ceramide-phospholipid score in patients with stable coronary heart disease on optimal medical therapy[J/OL]. J Am Heart Assoc，2020，9（10）：e015258[2021-12-10]. ht tps://doi.org/10.1161/jaha.119.015258.
[14] NAKANE M，KUBOTA M，NAKAGOMI T，et al. Lethal forebrain ischemia stimulates sphingomyelin hydrolysis and ceramide generation in the gerbil hippocampus[J]. Neurosci Lett，2000，296（2/3）：89-92.
[15] KUBOTA M，NARITA K，NAKAGOMI T，et al. Sphingomyelin changes in rat cerebral cortex during focal ischemia[J]. Neurol Res，1996，18（4）：337-341.
[16] TAKAHASHI K，GINIS I，NISHIOKA R，et al. Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning[J]. J Cereb Blood Flow Metab，2004，24（6）：623-627.
[17] HADAS Y，VINCEK A S，YOUSSEF E，et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction[J]. Circulation，2020，141（11）：916-930.
[18] HOJJATI M R，LI Z，ZHOU H，et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in APOE-deficient mice[J]. J Biol Chem，2005，280（11）：10284-10289.
[19] SEAH J Y H，CHEW W S，TORTA F，et al. Plasma sphingolipids and risk of cardiovascular diseases：a large-scale lipidomic analysis[J/OL]. Metabolomics，2020，16（9）：89[2021-11-11]. https://doi.org/10.1007/s11306-020-01709-8.
[20] VASILE V C，MEEUSEN J W，MEDINA INOJOSA J R，et al. Ceramide scores predict cardiovascular risk in the community[J].Arterioscler Thromb Vasc Biol，2021，41（4）：1558-1569. .
[21] GUI Y K，LI Q，LIU L，et al. Plasma levels of ceramides relate to ischemic stroke risk and clinical severity[J/OL]. Brain Res Bull，2020，158：122-127[2021-11-11]. https://doi.org/10.1016/j.brainresbull.2020.03.009.
[22] YOU Q，PENG Q，YU Z，et al. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease[J]. Biosci Rep，2020，40（9）：BSR20201519[2021-11-11]. https://doi.org/10.1042/bsr20201519.
[23] FIEDOROWICZ A，KOZAK-SYKAŁA A，BOBAKŁ，et al. Ceramides and sphingosine-1-phosphate as potential markers in diagnosis of ischaemic stroke[J].Neurol Neurochir Pol，2019，53（6）：484-491.